AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31607604
Drug: Oral poliovirus
RxNorm normalized name: poliovirus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral poliovirus vaccine (OPV) co-administered with RV3-BB
Trial: 31607604
Drug: Inactivated polio
RxNorm normalized name: Inactivated polio vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated polio vaccine (IPV) co-administered with RV3-BB
Trial: 7747098
Drug: Oral poliovirus
RxNorm normalized name: poliovirus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral poliovirus vaccine (OPV)
Trial: 26242222
Drug: Test capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Test capecitabine tablets (T)
Trial: 26242222
Drug: Reference capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Reference capecitabine tablets (R)
Trial: 24041978
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus progestin (E+P) therapy
Trial: 16217004
Drug: Obstetrician/gynecologists and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obstetrician/gynecologists and family medicine physicians
Trial: 10366230
Drug: Generalized chronic
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generalized chronic inflammatory demyelinating polyneuropathy (G-CIDP)
Trial: 7717597
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment with antimicrobial therapy for 7 days
Trial: 2392131
Drug: trimethoprim-sulfamethoxazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trimethoprim-sulfamethoxazole (20 and 100 mg per kilogram of body weight per day)
Trial: 2392131
Drug: trimethoprim-dapsone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trimethoprim-dapsone (20 mg per kilogram per day and 100 mg per day)
Trial: 31156265
Drug: Karo Light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Karo Light syrup
Trial: 31156265
Drug: Crown Lily
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crown Lily White syrup
Trial: 29040837
Drug: Grape intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape intake (5 g/kg body weight/day for 3 weeks)
Trial: 26611434
Drug: 100mg enteric-coated
RxNorm normalized name: tiopronin
DrugBank: Tiopronin (DB06823)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg enteric-coated aspirin
Trial: 19390079
Drug: Antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet therapy during coiling
Trial: 19390079
Drug: Antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet therapy after coiling
Trial: 19390079
Drug: No antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiplatelet therapy during coiling
Trial: 19390079
Drug: No antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiplatelet therapy after coiling
Trial: 17272770
Drug: Above median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Above median hsCRP level (> or =0.21 mg/L)
Trial: 16276447
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL 2% lidocaine and 0.5 mL betamethasone (7 mg/mL)
Trial: 16276447
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL 1% lidocaine and 0.5 mL betamethasone (7 mg/mL)
Trial: 26938637
Drug: Ginkgo Biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo Biloba (120 mg, 240 mg)
Trial: 26938637
Drug: Ginseng (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginseng (500 mg, 1000 mg)
Trial: 23176985
Drug: G1: hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G1: hyperbaric bupivacaine (8 mg), sufentanil (2.5 μg), morphine (100 μg)
Trial: 23176985
Drug: G2: hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G2: hyperbaric bupivacaine (10 mg), sufentanil (2.5 μg), morphine (100 μg)
Trial: 23176985
Drug: G3: hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G3: hyperbaric bupivacaine (12.5 mg), morphine (100 μg)
Trial: 23176985
Drug: G4: hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G4: hyperbaric bupivacaine (15 mg), morphine (100 μg)
Trial: 23176985
Drug: G5: hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G5: hyperbaric bupivacaine (12.5 mg), morphine (100 μg), without perioperative anti‐inflammatory
Trial: 12145066
Drug: Isoflurane inhalation
RxNorm normalized name: isoflurane INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflurane inhalation
Trial: 12145066
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of isoflurane and propofol
Trial: 7308277
Drug: Atenolol 100
RxNorm normalized name: atenolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 100 mg once/day
Trial: 7308277
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg twice/day
Trial: 7308277
Drug: Metoprolol 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 300 mg once/day
Trial: 31999296
Drug: High-Dose Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Dose Chemotherapy (HDCT)
Trial: 31999296
Drug: Conventional-Dose Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-Dose Chemotherapy (CDCT)
Trial: 26777124
Drug: Accelerated radiotherapy
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated radiotherapy (AF) - 1.1+2.0 Gy/day, 5 days/week in 35 days, total dose 68 Gy
Trial: 26777124
Drug: Conventional radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional radiotherapy (CF) - 2 Gy/day, 5 days/week in 49 days, total dose 68 Gy
Trial: 20518928
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group I: 2 mL of distilled water
Trial: 9162604
Drug: Lipid-lowering drugs
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering drugs in patients with CHD and serum cholesterol >5.5 mmol I(‐1)
Trial: 9162604
Drug: Consider lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consider lipid-lowering drugs in patients without CHD when serum cholesterol exceeds 6.5 mmol I(‐1) and CHD risk >20% over the next 10 years
Trial: 9162604
Drug: Dietary therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary therapy aimed at decreasing fat intake, particularly saturated fat, and weight reduction in the obese
Trial: 29708630
Drug: Topical timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical timolol 0.5% cream
Trial: 29708630
Drug: Intralesional injection
RxNorm normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of diprospan combined with topical timolol 0.5% cream
Trial: 26079636
Drug: Anodal tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anodal tDCS combined with occupational therapy
Trial: 26079636
Drug: Sham tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham tDCS combined with occupational therapy
Trial: 24763401
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment response assessed by leukemic blast counts in bone marrow on day 28 after first reinduction.
Trial: 24763401
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment response assessed by leukemic blast counts in bone marrow on day 15 after first reinduction.
Trial: 17109859
Drug: Outpatient Thermachoice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient Thermachoice III with ibuprofen 800 mg pre-treatment and nitrous oxide rescue analgesia
Trial: 16331821
Drug: TCI remifentanil‐propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCI remifentanil‐propofol (remifentanil at 6 microg/L and propofol at 3 mg/L)
Trial: 16331821
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (fentanyl 2.5 microg/kg and propofol 1‐2 mg/kg, maintained with fentanyl 0.03 microg.kg(‐1).min(‐1) and 1% isoflurane)
Trial: 9862539
Drug: Percutaneous intramuscular
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous intramuscular stimulation
Trial: 30973188
Drug: Dexamethasone 1
RxNorm normalized name: dexamethasone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 1 mg
Trial: 23082002
Drug: Vismodegib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vismodegib (150 mg/day orally) with FOLFOX or FOLFIRI plus bevacizumab (5 mg/kg every 2 weeks)
Trial: 23082002
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with FOLFOX or FOLFIRI plus bevacizumab (5 mg/kg every 2 weeks)
Trial: 8201151
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin therapy
Trial: 8772731
Drug: Intensified Conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified Conventional Insulin Treatment (ICT)
Trial: 8772731
Drug: Standard Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Insulin Treatment (ST)
Trial: 1595825
Drug: Adaptive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive group (n = 23) received individual training in food preparation activities
Trial: 6529680
Drug: Midazolam 0.2
RxNorm normalized name: midazolam 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.2 mg X kg‐1
Trial: 6529680
Drug: Midazolam 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.4 mg X kg‐1
Trial: 28194841
Drug: Sildenafil treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil treatment in HFpEF patients
Trial: 26464415
Drug: EA+LA (Electroacupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EA+LA (Electroacupuncture after injection of local anaesthetics)
Trial: 24263121
Drug: Atropine (0.2-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.2-1 mg) during DSE
Trial: 21864414
Drug: Psycho-social intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psycho-social intervention consisting of 12 sessions of structured social support, problem solving techniques, group discussions, and trainer-supervised relaxation exercises (twice per week over six weeks)
Trial: 19212235
Drug: Immediately loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately loaded dental implants
Trial: 19212235
Drug: Conventionally loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventionally loaded dental implants
Trial: 11555565
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg aerosolized tobramycin solution for inhalation (TSI) administered twice daily for 4 weeks
Trial: 11555565
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg aerosolized tobramycin solution for inhalation (TSI)
Trial: 23923408
Drug: Methotrexate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (10 mg) single morning dose
Trial: 23923408
Drug: Mini pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini pulse betamethasone (5 mg) single morning dose on 2 consecutive days
Trial: 16515981
Drug: Baseline PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline PSA less than 1 ng/ml
Trial: 16515981
Drug: Baseline PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline PSA 1.0 to 1.99 ng/ml
Trial: 16515981
Drug: Baseline PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline PSA 2.0 to 2.99 ng/ml
Trial: 16515981
Drug: Baseline PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline PSA 3.0 to 4.0 ng/ml
Trial: 16515981
Drug: Men with
RxNorm normalized name: Peptamen with Prebio Vanilla
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Men with baseline PSA less than 1 ng/ml converting to PSA more than 4 ng/ml
Trial: 16515981
Drug: Men with
RxNorm normalized name: Peptamen with Prebio Vanilla
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Men with baseline PSA less than 1 ng/ml and negative baseline DRE
Trial: 10691220
Drug: M‐6‐G 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M‐6‐G 0.1 mg/kg
Trial: 1972381
Drug: Morphine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.15 mg/kg
Trial: 9488217
Drug: Acetylcholine (ACh)
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylcholine (ACh) at doses of 0.3, 1.0, and 3.0 microg/kg per min
Trial: 9488217
Drug: Atropine at
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine at doses of 100 and 300 ng/kg per min
Trial: 8442923
Drug: Chemotherapy (tinidazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (tinidazole, thiabendazole, and cotrimoxazole)
Trial: 2908258
Drug: Chloroquine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (300 mg per week)
Trial: 29914406
Drug: Management strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management strategies by general practitioners (GPs) during MUS consultations, including history-taking, physical examination (24.5%), additional investigations by the GP (11.1%), prescribing medication (24.6%), and providing explanations (11.2%).
Trial: 24919867
Drug: Data from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Data from the Clinical Antipsychotic Trial of Intervention and Effectiveness
Trial: 20651386
Drug: Prospective follow‐up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prospective follow‐up without treatment
Trial: 18614918
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) adherence measured through pill usage and questionnaire.
Trial: 18614918
Drug: Complete adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete adherence (100% drug possession ratio).
Trial: 12626218
Drug: 5-cm² Estradot
RxNorm normalized name: estradiol 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-cm² Estradot patch (50 micro g/day)
Trial: 12626218
Drug: 12.5-cm² Climara
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5-cm² Climara patch
Trial: 12626218
Drug: 5-cm² Estradot
RxNorm normalized name: estradiol 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-cm² Estradot patch
Trial: 12626218
Drug: Both patches
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both patches
Trial: 10652894
Drug: Nimesulide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide (100 mg) tablets administered twice daily
Trial: 10652894
Drug: Diclofenac (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (50 mg) tablets administered thrice daily
Trial: 6149772
Drug: Dextroamphetamine 30
RxNorm normalized name: dextroamphetamine 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine 30 mg
Trial: 31695864
Drug: MART (maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MART (maintenance and reliever therapy)
Trial: 29193710
Drug: Scopolamine ointment
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Scopolamine ointment
Trial: 25172200
Drug: Collagen sponge
RxNorm normalized name: Absorbable collagen sponge bone graft product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen sponge without antibiotics
Trial: 11907654
Drug: Rapid fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid fat infusion over 6 h (rFI)
Trial: 11907654
Drug: Slow fat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow fat infusion over 24 h (sFI)
Trial: 10208786
Drug: No intra-aortic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intra-aortic balloon pump therapy
Trial: 2365119
Drug: Piperacillin or
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piperacillin or Mezlocillin (single-dose prophylaxis)
Trial: 330077
Drug: timolol (20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: timolol (20, 40, and 60 mg daily)
Trial: 330077
Drug: propranolol (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propranolol (0.2 mg/kg intravenously)
Trial: 7245774
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg slow-release allopurinol
Trial: 29474280
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of oral phenazopyridine
Trial: 22412865
Drug: Late exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late exposure group (LEG) - Sulfadoxine-Pyrimethamine (SP) plus Artesunate (AS) from 2.5-4.5 months of age and monthly placebo from 5.5-9.5 months
Trial: 20631460
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac sodium 1% gel (DSG) applied 4 g, 4 times daily
Trial: 20631460
Drug: Vehicle (control)
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (control) applied 4 g, 4 times daily
Trial: 21174485
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac sodium 1% gel (DSG)
Trial: 17397001
Drug: peginterferon-alpha 2a/ribavirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon-alpha 2a/ribavirin therapy
Trial: 15719490
Drug: Raltitrexed at
RxNorm normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltitrexed at a dose of 2.5 mg/m(2) intravenously (i.v), once every 3 weeks, for two doses, combined with standard radiotherapy of 70 Gy over 7 weeks.
Trial: 15719490
Drug: Raltitrexed at
RxNorm normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltitrexed at a dose of 2.5 mg/m(2) given twice 3 weeks apart, combined with 70 Gy of radiotherapy.
Trial: 12112183
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate 2 x 240 mg
Trial: 7749498
Drug: Standard intensive
RxNorm normalized name: MACADAMIA OIL 2 g in 100 g / CERAMIDE NP 0.0006 g in 100 g / PANTHENOL 0.75 g in 100 g / CENTELLA ASIATICA WHOLE 0.003 g in 100 g TOPICAL CREAM [ATO STANDARD INTENSIVECREAM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intensive treatment and patient education with the distress reduction program
Trial: 7749498
Drug: Standard intensive
RxNorm normalized name: MACADAMIA OIL 2 g in 100 g / CERAMIDE NP 0.0006 g in 100 g / PANTHENOL 0.75 g in 100 g / CENTELLA ASIATICA WHOLE 0.003 g in 100 g TOPICAL CREAM [ATO STANDARD INTENSIVECREAM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intensive treatment and patient education without the distress reduction program
Trial: 373084
Drug: Tolfenamic acid
RxNorm normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolfenamic acid 600 mg daily
Trial: 1096276
Drug: Phenylbutazone 300
RxNorm normalized name: phenylbutazone 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylbutazone 300 mg daily
Trial: 373084
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 1,500 mg daily
Trial: 28009472
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg for 1 month (TP1)
Trial: 28009472
Drug: Linagliptin 5
RxNorm normalized name: linagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin 5 mg (TP2)
Trial: 28009472
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg (TP1)
Trial: 19753648
Drug: G-CSF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (5 microg/kg/day for 5-7 days)
Trial: 19753648
Drug: Triple group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple group (GM-CSF 10 microg/kg/day on 1st and 2nd day, G-CSF 5 microg/kg/day for 5-7 days, and darbepoetin-alpha 40 mg on 1st day)
Trial: 17499604
Drug: Celecoxib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (200 mg twice daily) + Esomeprazole (20 mg twice daily)
Trial: 17499604
Drug: Celecoxib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (200 mg twice daily) + Placebo
Trial: 12468168
Drug: Lidocaine ointment
RxNorm normalized name: Lidocaine Ointment
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine ointment